Dana V. Rizk

Dana Rizk practices at Springs Dialysis in Pompano Beach, Florida.

Dana Rizk's NPI, 1356378335, was assigned on June 27, 2006. Dana Rizk holds Alabama license 28799.

Dana Rizk's primary practice is Springs Dialysis, at 3890 Park Central N Blvd, Pompano Beach, FL 33064 in Broward County. The practice phone is (205) 655-0871.

Dana Rizk's primary practice is Springs Dialysis in Pompano Beach, Florida. Dana Rizk is also affiliated with UAB Hospital. The medical group on file is UAB Medicine. Dmand AI also links Dana Rizk to 1 more dialysis center, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dana Rizk practices, 2 sites in all. Vendor and product names are available with a free account.

Nephrology is Dana Rizk's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dana Rizk is licensed in Alabama.

CMS data shows 229 Medicare services from Dana Rizk across 7 procedure codes in 2024, for 94 Medicare patients. Medicare paid $33,061 for them.

CMS counts 94 Medicare patients who saw Dana Rizk in 2024. The largest group is 65 to 74, with 41 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 30% are also on Medicaid. Their average risk score is 4.56, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dana Rizk's median patient age at 56, with 52% women.

In 2024, Dana Rizk wrote 552 Medicare Part D claims for 110 patients. 84% of them were for generic drugs. CMS names the drug for 378 of them, across 13 drugs with 11 or more claims each, at $48,030 in total drug cost. In 2023, CMS named 387 claims across 17 drugs.

Dana Rizk accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 68 papers to Dana Rizk, published from 2011 to 2025. 2023 was the busiest year, with 9. The most frequent topics are Glomerulonephritis, IGA, Renal Insufficiency, Chronic and Immunoglobulin A. Dana Rizk has published most often in Kidney Int. Dana Rizk's most frequent co-authors are Bruce A. Julian, Jan M. Novak, MD and David G. Warnock, MD.

Dmand AI links Dana Rizk to 7 clinical trials, 3 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Glomerulonephritis, IGA, Nephritis, Hereditary and Polycystic Kidney, Autosomal Dominant. Biogen sponsors the most, 4. Open Payments lists research payments to Dana Rizk that name 1 trial.

CMS Open Payments shows 128 general payments to Dana Rizk from 19 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 87% of the total. Otsuka Pharmaceutical Development & Commercialization, Inc. paid the most, $79,858. It also lists 38 research payments totaling $42,438 from 2019 to 2025, naming 1 clinical trial.